Meeting
2018 ASCO Annual Meeting
Role of melanoma cell-intrinsic RIG-I and STING signaling for checkpoint inhibitor‑mediated anticancer immunity.
Authors
Simon Heidegger
Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Simon Heidegger , Alexander Wintges , Sarah Bek , Martina Schmickl , Julius Fischer , Paul-Albert Koenig , Tobias Haas , Hendrik Poeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3081)
DOI
10.1200/JCO.2018.36.15_suppl.3081
Abstract #
3081
Poster Bd #
295
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Potency of CD8+ T-cell mediated antitumor immunity from intratumoral immunotherapy with STING agonist, ADU-S100, in an esophageal adenocarcinoma model.
First Author: Laila Babar
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2024 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.
First Author: Panpan Zhang
Poster
2023 ASCO Breakthrough
Efficacy of PD-1 inhibitors in the treatment of advanced gastrointestinal tumors and the effect on T-lymphocyte subsets and IL-6 levels in patients.
First Author: XinCheng He